XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 29.97%5.53B | 29.74%1.79B | 33.25%1.43B | 31.39%1.25B | 24.66%1.07B | 14.43%4.25B | 16.48%1.38B | 13.07%1.07B | 22.12%950.31M | 5.64%855.28M |
Operating revenue | 41.23%5.53B | 45.89%1.79B | 30.56%1.31B | 31.39%1.25B | 21.18%956.6M | 8.72%3.91B | 8.87%1.22B | 8.11%1B | 26.21%950.31M | -1.02%789.4M |
Cost of revenue | 22.20%2.87B | 25.59%947.72M | 25.46%731.56M | 17.05%647.76M | 18.66%539.61M | 1.68%2.35B | -0.62%754.6M | -3.36%583.12M | 13.70%553.39M | -0.65%454.74M |
Gross profit | 39.53%2.66B | 34.77%839.47M | 42.57%695.01M | 51.39%600.9M | 31.48%526.62M | 35.29%1.91B | 47.15%622.9M | 41.93%487.49M | 36.18%396.92M | 13.81%400.54M |
Operating expense | 31.52%2.02B | 21.49%634.35M | 31.00%514.75M | 45.64%497.06M | 33.74%371.68M | 40.91%1.53B | 41.31%522.14M | 67.64%392.95M | 33.65%341.29M | 21.08%277.91M |
Selling and administrative expenses | 30.48%1.68B | 20.81%547.51M | 26.39%419.94M | 45.22%407.01M | 37.82%302.08M | 47.16%1.28B | 44.42%453.18M | 84.14%332.25M | 39.20%280.28M | 23.44%219.19M |
-Selling and marketing expense | 38.50%1.24B | 28.83%424.55M | 44.91%300.84M | 45.54%303.19M | 41.05%214.57M | 44.32%897.59M | 52.12%329.55M | 55.93%207.6M | 42.06%208.32M | 21.17%152.12M |
-General and administrative expense | 11.90%433.4M | -0.54%122.96M | -4.46%119.1M | 44.28%103.83M | 30.48%87.51M | 54.18%387.32M | 27.23%123.63M | 163.55%124.66M | 31.53%71.96M | 28.91%67.07M |
Research and development costs | 36.85%341.29M | 25.92%86.83M | 56.21%94.81M | 47.59%90.05M | 18.51%69.6M | 15.64%249.39M | 23.79%68.96M | 12.46%60.69M | 12.96%61.01M | 13.00%58.73M |
Operating profit | 72.44%644.16M | 103.59%205.12M | 90.66%180.26M | 86.65%103.84M | 26.35%154.94M | 16.24%373.56M | 87.25%100.75M | -13.32%94.55M | 54.11%55.63M | 0.20%122.63M |
Net non-operating interest income expense | -41.88%-63.72M | -5.17%-17.23M | -30.09%-16.92M | -111.12%-14.84M | -73.42%-14.72M | -66.20%-44.91M | -93.69%-16.39M | -53.36%-13M | -15.68%-7.03M | -112.01%-8.49M |
Non-operating interest expense | 41.88%63.72M | 5.17%17.23M | 30.09%16.92M | 111.12%14.84M | 73.42%14.72M | 66.20%44.91M | 93.69%16.39M | 53.36%13M | 15.68%7.03M | 112.01%8.49M |
Other net income (expense) | 77.47%-7.98M | -489.74%-22.95M | 288.08%11.03M | 102.11%689K | 216.83%3.25M | -564.25%-35.43M | -64.25%5.89M | -388.49%-5.87M | -369.06%-32.67M | 28.88%-2.78M |
Other non- operating income (expenses) | 77.47%-7.98M | -489.74%-22.95M | 288.08%11.03M | 102.11%689K | 216.83%3.25M | -564.25%-35.43M | -64.25%5.89M | -388.49%-5.87M | -369.06%-32.67M | 28.88%-2.78M |
Income before tax | 95.23%572.47M | 82.75%164.94M | 130.41%174.38M | 462.93%89.68M | 28.83%143.47M | -2.90%293.23M | 46.00%90.26M | -26.26%75.68M | -30.90%15.93M | -2.72%111.36M |
Income tax | 6.03%133.76M | -11.50%36.23M | -26.18%42.05M | 441.50%21.63M | 39.53%33.86M | 81.17%126.15M | 169.66%40.93M | 155.13%56.96M | -39.11%4M | -5.09%24.27M |
Net income | 162.57%438.71M | 160.96%128.72M | 606.81%132.33M | 470.11%68.05M | 25.85%109.61M | -28.09%167.08M | 5.76%49.32M | -76.69%18.72M | -27.64%11.94M | -2.04%87.1M |
Net income continuous Operations | 162.57%438.71M | 160.96%128.72M | 606.81%132.33M | 470.11%68.05M | 25.85%109.61M | -28.09%167.08M | 5.76%49.32M | -76.69%18.72M | -27.64%11.94M | -2.04%87.1M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 162.57%438.71M | 160.96%128.72M | 606.81%132.33M | 470.11%68.05M | 25.85%109.61M | -28.09%167.08M | 5.76%49.32M | -76.69%18.72M | -27.64%11.94M | -2.04%87.1M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 162.57%438.71M | 160.96%128.72M | 606.81%132.33M | 470.11%68.05M | 25.85%109.61M | -28.09%167.08M | 5.76%49.32M | -76.69%18.72M | -27.64%11.94M | -2.04%87.1M |
Basic earnings per share | 161.67%3.14 | 162.86%0.92 | 623.08%0.94 | 444.44%0.49 | 25.40%0.79 | -28.22%1.2 | 4.30%0.35 | -77.50%0.13 | -24.17%0.09 | -1.52%0.63 |
Diluted earnings per share | 159.17%3.11 | 160.00%0.91 | 623.08%0.94 | 433.33%0.48 | 23.81%0.78 | -28.22%1.2 | 4.30%0.35 | -77.50%0.13 | -24.17%0.09 | -1.52%0.63 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |